In addition, despite the exciting results of nangibotide, the other TREM-1 inhibitors should also be further developed and brought into clinical trial phase in order to test and develop other substances beside nangibotide in the treatment of sepsis and septic shock. The gene discussed is TREM1; the disease is Sepsis.